View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter’s Weekly Newsletter
Keith Flaherty is the director of clinical research at the Massachusetts General Hospital Cancer Center and a previous guest on The Drive. In this episode, Keith first delves into the statistics on cancer's prevalence as we age, underscoring the significance of finding effective treatments and early detection methodologies. He touches on the history of cancer therapeutics and illuminates the notable enhancements in cancer therapy within the last decade that are setting the stage for a promising future. He goes into detail on the potential of immunotherapy and therapies that can combat cancer’s evasive tactics while explaining some of the existing challenges around specificity, cost, and scalability. Additionally, Keith highlights the significant leap in early detection methodologies, namely liquid biopsies, which have the potential not only to determine if a cancer is present in an early stage, but also identify the possible tissue of origin.
We discuss:
Connect With Peter on Twitter, Instagram, Facebook and YouTube
#158 - Brian Deer: A tale of scientific fraud—exposing Andrew Wakefield and the origin of the belief that vaccines cause autism
#157 - AMA #22: Losing fat and gaining fat: the lessons of fat flux
#156 - Jake Muise: Humanely harvesting axis deer while alleviating its impact on Hawaii’s vulnerable ecosystems
#155 - Chris Sonnenday, M.D.: The history, challenges, and gift of organ transplantation
#154 - Steve Levitt, Ph.D.: A rogue economist’s view on climate change, mental health, the ethics of experiments, and more
#153 - AMA #21: Deep dive into olive oil, high-intensity exercise, book update, and more
#152 - Michael Rintala, D.C.: Principles of Dynamic Neuromuscular Stabilization (DNS)
#151 - Alex Hutchinson, Ph.D.: Translating the science of endurance and extreme human performance
#150 - Senator Bill Frist, M.D.: A modern Renaissance man's journey through science, politics, and business
#149 - AMA #20: Simplifying the complexities of insulin resistance: how it's measured, how it manifests in the muscle and liver, and what we can do about it
#148 - Richard Miller, M.D., Ph.D.: The gold standard for testing longevity drugs: the Interventions Testing Program
#147 - Hussein Yassine, M.D.: Deep dive into the “Alzheimer’s gene” (APOE), brain health, and omega-3s
#146 - Guy Winch, Ph.D.: Emotional first aid and how to treat psychological injuries
#145 - AMA #19: Deep dive on Zone 2 training, magnesium supplementation, and how to engage with your doctor
#144 - Phil Maffetone: Optimizing health and performance through maximal aerobic function
#143 - John Ioannidis, M.D., D.Sc.: Why most biomedical research is flawed, and how to improve it
#142 - Robert Abbott: The Bobby Knight story—a cautionary tale of unchecked anger, ego, and winning at all costs
#141 - AMA #18: Deep dive: sugar and sugar substitutes
#140 - Gerald Shulman, M.D., Ph.D.: A masterclass on insulin resistance—molecular mechanisms and clinical implications
#139 - Kristin Neff, Ph.D.: The power of self-compassion
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Huberman Lab
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.